Ratings GVS S.p.A.

Equities

GVS

IT0005411209

Market Closed - Borsa Italiana Other stock markets 11:44:59 2024-04-25 am EDT			5-day change	1st Jan Change
5.39 ^EUR	-2.00%		-4.77%	-3.32%

Apr. 09	Mib correction at 34,000; strength on Fincantieri	AN
Apr. 09	Lists bearish; DiaSorin rises against the tide	AN

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

The company is in debt and has limited leeway for investment
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the past year, analysts have significantly revised downwards their profit estimates.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' opinions have been revised negatively.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
GVS S.P.A.	-3.32%	1.03B		B
COLOPLAST A/S	+11.94%	29.7B		B+
SHANDONG WEIGAO GROUP MEDICAL POLYMER COMPANY LIMITED	-33.64%	2.9B		B-
WINNER MEDICAL CO., LTD.	-17.23%	2.71B		C+
INTCO MEDICAL TECHNOLOGY CO., LTD.	+6.12%	2.14B	-	A-
HARTALEGA HOLDINGS	-1.11%	1.91B		B
HARBIN FUERJIA TECHNOLOGY CO., LTD.	-12.82%	1.84B	-	-
TOP GLOVE CORPORATION BHD.	-7.22%	1.42B		B
NAKANISHI INC.	-2.49%	1.26B		-
KANGJI MEDICAL HOLDINGS LIMITED	+3.72%	1.13B		-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes